Patents by Inventor Kazunosuke AIDA
Kazunosuke AIDA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9320728Abstract: A method for producing a patch comprising a support layer and an adhesive agent layer arranged on at least one surface of the support layer, the method comprising: step A) obtaining an adhesive agent layer composition comprising free ropinirole in an amount which results in a content of 5 to 13.2% by mass in an obtained adhesive agent layer; step B) heating the adhesive agent layer composition at a temperature in a range from 50 to 76° C. for 5 minutes to 24 hours; and step C) cooling the heated adhesive agent layer composition to normal temperature at an average rate of temperature drop of 1 to 20° C./hour, thereby obtaining the adhesive agent layer comprising the free ropinirole at a supersaturated concentration in a dissolved form.Type: GrantFiled: June 27, 2014Date of Patent: April 26, 2016Assignee: HISAMITSU PHARMACEUTICAL CO., INC.Inventors: Takahito Yoshizaki, Kouji Tanaka, Kazunosuke Aida, Terumitsu Kaiho, Nobuo Tsutsumi
-
Publication number: 20150004215Abstract: A method for producing a patch comprising a support layer and an adhesive agent layer arranged on at least one surface of the support layer, the method comprising: step A) obtaining an adhesive agent layer composition comprising free ropinirole in an amount which results in a content of 5 to 13.2% by mass in an obtained adhesive agent layer; step B) heating the adhesive agent layer composition at a temperature in a range from 50 to 76° C. for 5 minutes to 24 hours; and step C) cooling the heated adhesive agent layer composition to normal temperature at an average rate of temperature drop of 1 to 20° C./hour, thereby obtaining the adhesive agent layer comprising the free ropinirole at a supersaturated concentration in a dissolved form.Type: ApplicationFiled: June 27, 2014Publication date: January 1, 2015Applicant: HISAMITSU PHARMACEUTICAL CO., INC.Inventors: Takahito YOSHIZAKI, Kouji Tanaka, Kazunosuke Aida, Terumitsu Kaiho, Nobuo Tsutsumi
-
Patent number: 8877235Abstract: A method for producing a patch comprising a support layer and an adhesive agent layer arranged on at least one surface of the support layer, the method comprising: a step A of obtaining an adhesive agent layer composition comprising oxybutynin hydrochloride as a drug, an acrylic-based polymer and/or a rubber-based polymer as an adhesive base agent, liquid paraffin, a sterol, an organic acid, and a tackifier; a step B of heating the adhesive agent layer composition at a temperature in a range from 55 to 70° C. for 1 to 24 hours; and a step C of cooling the heated adhesive agent layer composition to a temperature lower than room temperature at an average rate of temperature drop of 1 to 20° C./hour, thereby obtaining the adhesive agent layer comprising the drug at a supersaturated concentration in a dissolved form.Type: GrantFiled: June 21, 2013Date of Patent: November 4, 2014Assignee: Hisamitsu Pharmaceutical Co., Inc.Inventors: Kazunosuke Aida, Terumitsu Kaiho, Tetsurou Tateishi, Nobuo Tsutsumi
-
Patent number: 8802134Abstract: A method for producing a patch having a high skin penetrability and a high pharmaceutical physical properties such as adhesion and cohesiveness, and a long-term storability. The patch is produced by first obtaining an adhesive agent layer composition containing oxybutynin and/or salt thereof as a drug, an acrylic-based polymer and/or a rubber-based polymer as an adhesive base agent, liquid paraffin, an organic acid, and a tackifier; heating the adhesive agent layer composition at a temperature in a range from a melting point of the drug to a temperature higher than the melting point by 10° C. for 2 to 24 hours; and slowly cooling the heated adhesive agent layer composition to obtain the adhesive agent layer comprising the drug at a supersaturated concentration in a dissolved form.Type: GrantFiled: February 21, 2013Date of Patent: August 12, 2014Assignee: Hisamitsu Pharmaceutical Co., Inc.Inventors: Naruhito Higo, Tetsurou Tateishi, Takaaki Terahara, Kazunosuke Aida, Shigeki Hayashi, Nobuo Tsutsumi
-
Publication number: 20140186428Abstract: A method for producing a patch comprising a support layer and an adhesive agent layer arranged on at least one surface of the support layer, the method comprising: a step A of obtaining an adhesive agent layer composition comprising oxybutynin hydrochloride as a drug, an acrylic-based polymer and/or a rubber-based polymer as an adhesive base agent, liquid paraffin, a sterol, an organic acid, and a tackifier; a step B of heating the adhesive agent layer composition at a temperature in a range from 55 to 70° C. for 1 to 24 hours; and a step C of cooling the heated adhesive agent layer composition to a temperature lower than room temperature at an average rate of temperature drop of 1 to 20° C./hour, thereby obtaining the adhesive agent layer comprising the drug at a supersaturated concentration in a dissolved form.Type: ApplicationFiled: June 21, 2013Publication date: July 3, 2014Inventors: Kazunosuke AIDA, Terumitsu KAIHO, Tetsurou TATEISHI, Nobuo TSUTSUMI
-
Publication number: 20140161865Abstract: A method for producing a patch having a high skin penetrability and a high pharmaceutical physical properties such as adhesion and cohesiveness, and a long-term storability. The patch is produced by first obtaining an adhesive agent layer composition containing oxybutynin and/or salt thereof as a drug, an acrylic-based polymer and/or a rubber-based polymer as an adhesive base agent, liquid paraffin, an organic acid, and a tackifier; heating the adhesive agent layer composition at a temperature in a range from a melting point of the drug to a temperature higher than the melting point by 10° C. for 2 to 24 hours; and slowly cooling the heated adhesive agent layer composition to obtain the adhesive agent layer comprising the drug at a supersaturated concentration in a dissolved form.Type: ApplicationFiled: February 21, 2013Publication date: June 12, 2014Applicant: HISAMITSU PHARMACEUTICAL CO., INC.Inventors: Naruhito Higo, Tetsurou Tateishi, Takaaki Terahara, Kazunosuke Aida, Shigeki Hayashi, Nobuo Tsutsumi
-
Patent number: 8691267Abstract: A patch comprising a backing layer and an adhesive layer disposed on the backing layer and compounded with a drug and an adhesive base agent, wherein the adhesive base agent comprises styrene-isoprene-styrene block copolymer, 2-ethylhexyl acrylate-vinyl acetate copolymer and a basic nitrogen-including polymer including a basic nitrogen and having no adhesion property at normal temperature.Type: GrantFiled: August 7, 2003Date of Patent: April 8, 2014Assignee: Hisamitsu Pharmaceutical Co., Inc.Inventors: Takaaki Terahara, Kazunosuke Aida, Arata Toshimitsu, Naruhito Higo
-
Publication number: 20130053358Abstract: Provided is a transdermal preparation having low skin irritation as well as a sufficient skin permeability rate of donepezil, which comprises one or more drugs selected from donepezil and pharmaceutically acceptable salts thereof. Also provided are a manufacturing method thereof, and a method for reducing skin irritation of a transdermally absorbable donepezil-containing preparation. An embodiment is a transdermal preparation comprising one or more drugs selected from donepezil and pharmaceutically acceptable salts thereof, and a skin irritation-reducing agent.Type: ApplicationFiled: April 27, 2011Publication date: February 28, 2013Applicant: HISAMITSU PHARMACEUTICAL CO., INC.Inventors: Kazunosuke Aida, Yasunari Michinaka, Kenji Atarashi, Yasunori Takada
-
Publication number: 20130053357Abstract: Provided is a skin irritation suppressant for transdermal preparations, having a sufficient reduction effect of skin irritation due to a drug. Also provided is a transdermal preparation comprising the skin irritation suppressant. One embodiment of the invention is a skin irritation suppressant for suppressing the skin irritation due to a drug and a pharmaceutical ingredient to be used in a transdermal preparation other than the drug, the skin irritation suppressant comprising a sterol compound selected from the group consisting of cholesterol, cholesterol derivatives and cholesterol analogs, and the drug is one or more basic drugs selected from the group consisting of tolterodine, asenapine, bisoprolol, risperidone, nicotine and citalopram, and their pharmaceutically acceptable salts.Type: ApplicationFiled: April 27, 2011Publication date: February 28, 2013Applicant: HISAMITSU PHARMACEUTICAL CO., INC.Inventors: Hidekazu Kuma, Kenji Atarashi, Kazuhiro Suzuki, Kazunosuke Aida
-
Publication number: 20090208560Abstract: A cover material adapted to cover the entirety of a patch is provided. The cover material has a support layer and, superimposed on a surface thereof, a pressure sensitive adhesive layer. The patch has a support film with a thickness of 12- to 30 ?m and, superimposed thereon, a drug containing layer. The cover material may be attached to the surface of the support film and to the skin around the patch so that the pressure sensitive adhesive layer is brought into contact with edges of the drug containing layer. Additionally, the pressure sensitive adhesive layer contains an adhesive resulting from the polymerization of vinyl acetate or N-vinyl-2-pyrrolidone and a C8 alkyl (meth)acrylate as essential monomers. Thus, there is provided a cover material that, when a patch medicated with, for example, mesylic acid pergolide is fixed on diseased part, such as, a part of the skin, by covering the patch, is capable of reducing irritation, etc. on the diseased part.Type: ApplicationFiled: April 24, 2009Publication date: August 20, 2009Applicant: HISAMITSU PHARMACEUTICAL CO., INC.Inventors: Kazunosuke AIDA, Arata TOSHIMITSU, Takaaki TERAHARA, Naruhito HIGO
-
Publication number: 20090175929Abstract: Disclosed is a donepezil-containing transdermally absorbable preparation which develops reduced adverse side effects and shows a satisfactory level of therapeutic effect. The preparation comprises an adhesive and a donepezil component (containing crystalline donepezil having type-B crystal polymorphism) and/or a salt thereof, wherein the donepezil component or the salt thereof is contained in an amount of 9 to 50% by mass relative to the total weight of the adhesive. The preparation (particularly, one having a non-aqueous adhesive layer) shows an excellent penetration of donepezil and/or a salt thereof into the skin, retains good stability of the active ingredient therein, and is remarkably reduced in local stimulation and adverse side effects.Type: ApplicationFiled: May 8, 2007Publication date: July 9, 2009Inventors: Takaaki Terahara, Yasunari Michinaka, Kazunosuke Aida, Masaru Nakanishi, Wataru Hattori, Takao Kuroda
-
Publication number: 20080188509Abstract: It is intended to provide pergolide-containing transdermal preparations having reduced side effects and exerting sufficient therapeutic effects. Namely, a pergolide-containing transdermal preparation which is capable of achieving a plasma AUC ratio of pergolide or the like to at least one pergolide metabolite of 1:0.5 to 1:5; and/or transdermal preparation containing pergolide and/or a pharmaceutically acceptable salt thereof which is capable of achieving a ratio (A/B) of the maximum plasma level (A) of pergolide and/or a pharmaceutically acceptable salt thereof to the plasma level (B) thereof in the next administration of less than 2.Type: ApplicationFiled: March 31, 2008Publication date: August 7, 2008Inventors: Arata TOSHIMITSU, Kazunosuke AIDA, Takaaki TERAHARA, Naruhito HIGO
-
Publication number: 20080138388Abstract: It is intended to provide a transdermal absorption patch which is highly excellent in transdermal absorption properties and long-lasting drug effect even in the case where a drug-effect component contained in the transdermal absorption patch is a basic drug hardly soluble in a pressure-sensitive adhesive base, has a high stability of the drug contained therein with the passage of time and can achieve improvement in the compliance and simplification of the administration method. These problems can be solved by providing a transdermal absorption patch which contains a basic drug having an octanol/water partition coefficient (logarithm) in the free state of 3 or above, a pressure-sensitive adhesive base and a (meth)acrylic copolymer having carboxyl group.Type: ApplicationFiled: January 24, 2006Publication date: June 12, 2008Applicant: Hisamitsu Pharmaceutical Co., Inc.Inventors: Kazunosuke Aida, Yasunari Michinaka, Takaaki Terahara
-
Publication number: 20070190123Abstract: The present invention provides a cover material 10, adapted to be attached to skin in a manner covering over the entirety of a patch 20, comprising a pressure-sensitive adhesive layer 12 on one side of a support 11, wherein said patch 20 comprises a drug-containing layer 22 for contacting with the skin, said layer being provided on a support film 21 with a thickness of 12-30 ?m, and wherein the cover material 10 is adapted to be attached to said support film 21 and a region of the skin around said patch 20 in such a manner that the pressure-sensitive adhesive layer 12 contacts with the edges of the drug-containing layer 22, and the pressure-sensitive adhesive layer 12 comprises a pressure-sensitive adhesive obtained by polymerizing vinyl acetate or N-vinyl-2-pyrrolidone and a (meth)acrylic acid alkyl ester with a C8 alkyl group as essential monomer components.Type: ApplicationFiled: January 31, 2005Publication date: August 16, 2007Inventors: Kazunosuke Aida, Arata Toshimitsu, Takaaki Terahara, Naruhito Higo
-
Publication number: 20070082037Abstract: It is intended to provide pergolide-containing transdermal preparations having reducreduced side effects and exerting sufficient therapeutic effects. Namely, a pergolide-containing transdermal preparation which is capable of achieving a plasma AUC ratio of pergolide or the like to at least one pergolide metabolite of 1:0.5 to 1:5; and/or transdermal preparation containing pergolide and/or a pharmaceutically acceptable salt thereof which is capable of achieving a ratio (A/B) of the maximum plasma level (A) of pergolide and/or a pharmaceutically acceptable salt thereof to the plasma level (B) thereof in the next administration of less than 2.Type: ApplicationFiled: October 29, 2004Publication date: April 12, 2007Inventors: Arata Toshimitsu, Kazunosuke Aida, Takaaki Terahara, Naruhito Higo
-
Publication number: 20060110433Abstract: A patch comprising a backing layer and an adhesive layer disposed on the backing layer and compounded with an adhesive base agent and pergolide and/or a pharmaceutically acceptable salt thereof, wherein the adhesive base agent comprises an acrylic polymer including no substantial carboxyl group and hydroxyl group and having self-adhesion properties and a rubber polymer, and the weight ratio of the content of the acrylic polymer to the content of the rubber polymer is from 1:1 to 1:9.Type: ApplicationFiled: August 7, 2003Publication date: May 25, 2006Inventors: Takaaki Terahara, Kazunosuke Aida, Arata Toshimitsu, Naruhito Higo
-
Publication number: 20050260255Abstract: A patch comprising a backing layer and an adhesive layer disposed on the backing layer and compounded with a drug and an adhesive base agent, wherein the adhesive base agent comprises styrene-isoprene-styrene block copolymer, 2-ethylhexyl acrylate—vinyl acetate copolymer and a basic nitrogen-including polymer including a basic nitrogen and having no adhesion property at normal temperature.Type: ApplicationFiled: August 7, 2003Publication date: November 24, 2005Inventors: Takaaki Terahara, Kazunosuke Aida, Arata Toshimitsu, Naruhito Higo
-
Publication number: 20040241240Abstract: It is intended to provide external preparations for percutaneous application and compositions therefor whereby a hardly soluble drug such as a drug having an ergoline skeleton can be effectively absorbed via the skin into the blood under circulation while avoiding side effects on the digestive system observed in case of oral administration or side effects on the central system caused by a rapid increase in the concentration in the blood and a high adhesiveness to the skin can be established. This object can be established by composition characterized by containing a copolymer having N-vinyl-2-pyrrolidone as one of its constituents and percutaneous absorption preparations characterized by having a drug-containing adhesive layer containing such a composition and a support layer.Type: ApplicationFiled: June 28, 2004Publication date: December 2, 2004Inventors: Takaaki Terahara, Kazunosuke Aida, Naruhito Higo, Shuji Sato
-
Publication number: 20040028724Abstract: An adhesive pharmaceutical preparation of the percutaneous absorption type containing an acid addition salt of a basic drug or amphoteric drug, in which the medicinal component highly permeates the skin and which is reduced in skin irritation and excellent in physical stability. The preparation comprises an aminated polymer, a drug in the form of an acid addition salt, and a carboxylic acid or/and a salt thereof, and is characterized in that the content of the aminated polymer is up to 50 wt. % based on the whole preparation, the amount of the amino groups contained in the polymer is 0.5 mol or higher per mol of the drug, and the amount of the carboxylic acid or/and salt thereof is 1 to 10 mol per mol of the sum of the drug and the amino groups contained in the polymer.Type: ApplicationFiled: May 6, 2003Publication date: February 12, 2004Inventors: Takaaki Terahara, Kazunosuke Aida, Naruhito Higo, Shuji Sato